The verdict
Our read at a glance.
Whether the best pre-GLP-1 oral option remains useful now, and at what cost in tolerability.
- The signal
- The trial programme was strong for its era: phase 3 studies showed dose-dependent weight loss clearly exceeding placebo and exceeding what either component achieves alone, sustained over a year, with registered trials continuing including in adolescents and in obstructive sleep apnoea. Its efficacy still compares respectably against the older options, though not against GLP-1 receptor agonists. The limiting factors have always been tolerability and reproductive safety rather than whether it works.
- The unknown
- Long-term cognitive effects of chronic topiramate exposure at weight-management doses, which patients report and which are not well quantified over years.
- Our read
- A genuinely effective oral drug whose problems are not about whether it works. The teratogenic risk is manageable with a proper programme; the cognitive effects are the reason people stop, and they are the part most often described as mild in summaries and as intolerable by patients.
The mechanism
How it works.
Phentermine supplies noradrenergic appetite suppression through the hypothalamus, as it does alone. Topiramate's contribution to weight loss was discovered incidentally during its use as an anticonvulsant and migraine drug, and its mechanism there is genuinely multiple: it blocks voltage-gated sodium channels, enhances GABA-A signalling, antagonises AMPA and kainate glutamate receptors, and inhibits carbonic anhydrase. Which of those drives appetite reduction is not settled, though the glutamatergic and GABAergic effects on reward and satiety circuits are the usual explanation, with some contribution from taste alteration. Combining them allows lower doses of each than would be needed alone, which is what makes the combination more effective and better tolerated than escalating either drug - and the carbonic anhydrase inhibition explains the paraesthesia, the taste changes, the acidosis and the kidney stones.
Safety & regulatory boundary
The consequential part.
Approved for chronic weight management, with a risk evaluation and mitigation strategy because topiramate is teratogenic: it increases the risk of oral clefts when taken in the first trimester, so pregnancy testing and contraception requirements apply. Other documented effects include paraesthesia, dysgeusia, cognitive slowing and word-finding difficulty, metabolic acidosis, raised heart rate, kidney stones and acute angle-closure glaucoma. Phentermine's contraindications apply to the combination.
What's next
What we're watching.
Adolescent long-term data, and how it is positioned as oral GLP-1 agents arrive.
Context
Why this is discussed.
It produces substantially more weight loss than phentermine alone, it is oral and comparatively cheap, and it has an approved adolescent indication.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · PHASE2 · COMPLETED · 2021-03-31
ClinicalTrials.gov · PHASE4 · RECRUITING · 2023-08-29
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2026-11-01
ClinicalTrials.gov · PHASE2 · COMPLETED · 2021-08-04
ClinicalTrials.gov · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · 2022-07-07
ClinicalTrials.gov · PHASE2 · COMPLETED · 2019-11-21
ClinicalTrials.gov · NA · RECRUITING · 2023-06-19
Indexed literature (PubMed)12
Gudzune KA et al. · JAMA · 2024
Grunvald E et al. · Gastroenterology · 2022
Shi Q et al. · Lancet · 2024
Jordan G et al. · Gastrointest Endosc Clin N Am · 2024
Tak YJ et al. · Curr Obes Rep · 2021
Saunders KH et al. · Med Clin North Am · 2018
Khera R et al. · JAMA · 2016
Gadde KM et al. · Lancet · 2011
Lewis KH et al. · Curr Obes Rep · 2024
Alfaris N et al. · Expert Opin Pharmacother · 2015
Hainer V · Expert Opin Pharmacother · 2014
Katsi V et al. · Recent Pat Cardiovasc Drug Discov · 2013
Keep reading